CompletedPHASE2, PHASE3NCT02612129

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Studying Niemann-Pick disease type C

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ZevraDenmark
Principal Investigator
Karl-Eugen Mengel
SphinCS GmbH, Hochheim, Germany
Intervention
arimoclomol(drug)
Enrollment
50 enrolled
Eligibility
2-18 years · All sexes
Timeline
20162024

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02612129 on ClinicalTrials.gov

Other trials for Niemann-Pick disease type C

Additional recruiting or active studies for the same condition.

See all trials for Niemann-Pick disease type C

← Back to all trials